{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:19:43Z","timestamp":1783937983839,"version":"3.55.0"},"reference-count":59,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Background\/Objectives: Arterial hypertension (AH) and hepatitis C virus (HCV) infection are interlinked, with AH increasing the risk of severe liver disease and HCV contributing to cardiovascular issues. Treating HCV in hypertensive patients is critical, though data on direct-acting antivirals (DAAs) in this group remain limited. Methods: This retrospective study evaluated the effects of DAAs in AH patients with HCV using data from the 2015\u20132023 EpiTer-2 project, a multicenter study in Poland. Results: Among the 18,968 HCV-infected DAA-treated patients, 5976 had AH. These patients were older, predominantly women, and had higher rates of obesity, comorbidities, cirrhosis, hepatocellular carcinoma, and genotype 1b infection. Sustained virologic response rates were high and comparable between the AH and non-AH groups in the intent-to-treat (94.8% vs. 94.2%) and per-protocol analyses (97.6% vs. 97.6%). AH was not independently associated with treatment failure (OR 0.87, 95% CI: 0.69\u20131.10). Predictors of failure included genotype 3, decompensated liver function, cirrhosis, thrombocytopenia, and treatment with asunaprevir + daclatasvir. While therapy discontinuation was more common in the AH patients, most completed treatment, with fatigue being the most frequent adverse event. Although not directly evaluated, the overall safety outcomes suggest that potential drug\u2013drug interactions with antihypertensive therapies are unlikely to have a major clinical impact in routine practice. Conclusions: This study highlights the safety and efficacy of DAAs in AH patients and emphasizes the importance of early HCV detection and treatment in this population.<\/jats:p>","DOI":"10.3390\/v18070763","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T09:51:09Z","timestamp":1783936269000},"page":"763","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Are Direct-Acting Antivirals Effective and Safe for Hepatitis C Patients with Arterial Hypertension? Evidence from a Large Retrospective Real-World Study"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1180-9230","authenticated-orcid":false,"given":"Micha\u0142","family":"Brzd\u0119k","sequence":"first","affiliation":[{"name":"Collegium Medicum, Jan Kochanowski University, 25-317 Kielce, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4713-0801","authenticated-orcid":false,"given":"Piotr","family":"Rzymski","sequence":"additional","affiliation":[{"name":"Department of Environmental Medicine, Poznan University of Medical Sciences, 60-806 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0938-1084","authenticated-orcid":false,"given":"Dorota","family":"Zar\u0119bska-Michaluk","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Allergology, Jan Kochanowski University, 25-317 Kielce, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1601-1703","authenticated-orcid":false,"given":"Barbara","family":"Poniedzia\u0142ek","sequence":"additional","affiliation":[{"name":"Department of Environmental Medicine, Poznan University of Medical Sciences, 60-806 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6319-9278","authenticated-orcid":false,"given":"Beata","family":"Lorenc","sequence":"additional","affiliation":[{"name":"Pomeranian Center of Infectious Diseases, Medical University, 80-214 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0844-9158","authenticated-orcid":false,"given":"Hanna","family":"Berak","sequence":"additional","affiliation":[{"name":"Outpatient Clinic, Hospital for Infectious Diseases in Warsaw, 01-201 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W\u0142odzimierz","family":"Mazur","sequence":"additional","affiliation":[{"name":"Clinical Department of Infectious Diseases in Chorz\u00f3w, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6072-4559","authenticated-orcid":false,"given":"Justyna","family":"Janocha-Litwin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Wroc\u0142aw Medical University, 50-367 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5640-5432","authenticated-orcid":false,"given":"Magdalena","family":"Tudrujek-Zdunek","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Medical University of Lublin, 20-059 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3078-8604","authenticated-orcid":false,"given":"Marek","family":"Sitko","sequence":"additional","affiliation":[{"name":"Department of Infectious and Tropical Diseases, Jagiellonian University, 31-088 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0209-1930","authenticated-orcid":false,"given":"Jakub","family":"Klapaczy\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Hepatology, The National Institute of Medicine of the Ministry of Interior and Administration, 02-507 Warszawa, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Flisiak","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Medical University of Bia\u0142ystok, 15-089 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,12]]},"reference":[{"key":"ref_1","unstructured":"WHO (2023, May 14). Hepatitis C. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e29900","DOI":"10.1002\/jmv.29900","article-title":"Is There Still Hope for the Prophylactic Hepatitis C Vaccine? A Review of Different Approaches","volume":"96","author":"Rzymski","year":"2024","journal-title":"J. Med. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Rzymski, P., Brzd\u0119k, M., Dobrowolska, K., Poniedzia\u0142ek, B., Murawska-Ochab, A., Zar\u0119bska-Michaluk, D., and Flisiak, R. (2024). Like a Rolling Stone? A Review on Spontaneous Clearance of Hepatitis C Virus Infection. Viruses, 16.","DOI":"10.3390\/v16091386"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/CEJ.0000000000000885","article-title":"Changing Global Epidemiology of Chronic Hepatitis C Virus-Related Outcomes from 2010 to 2019: Cirrhosis Is the Growing Burden of Hepatitis C Virus-Related Disease","volume":"33","author":"Pham","year":"2024","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJMra2033539","article-title":"Extrahepatic Manifestations of Chronic HCV Infection","volume":"384","author":"Cacoub","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.medcli.2023.10.011","article-title":"Extrahepatic Manifestations of HCV Where Do We Stand?","volume":"162","author":"Mokhles","year":"2024","journal-title":"Med. Cl\u00edn."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Rajewski, P., Zar\u0119bska-Michaluk, D., Janczewska, E., Gietka, A., Mazur, W., Tudrujek-Zdunek, M., Tomasiewicz, K., Belica-Wdowik, T., Baka-\u0106wierz, B., and Dybowska, D. (2022). Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11175193"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Moukaled, S., De Anda-Duran, I., and Bazzano, L.A. (2025). Hypertension. International Encyclopedia of Public Health, Elsevier.","DOI":"10.1016\/B978-0-323-99967-0.00319-7"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","article-title":"The Global Epidemiology of Hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Boateng, E.B., and Ampofo, A.G. (2023). A Glimpse into the Future: Modelling Global Prevalence of Hypertension. BMC Public Health, 23.","DOI":"10.1186\/s12889-023-16662-z"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1365-2893.2007.00885.x","article-title":"Co-Morbid Medical and Psychiatric Illness and Substance Abuse in HCV-Infected and Uninfected Veterans","volume":"14","author":"Butt","year":"2007","journal-title":"J. Viral Hepat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/apt.12234","article-title":"Associations of Chronic Hepatitis C with Metabolic and Cardiac Outcomes","volume":"37","author":"Younossi","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1253\/circj.CJ-18-0459","article-title":"Hepatitis C Virus and Cardiovascular Disease","volume":"82","author":"Onoue","year":"2018","journal-title":"Circ. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijcard.2011.07.016","article-title":"Effects of Hepatitis C Virus on Cardiovascular Risk in Infected Patients: A Comparative Study","volume":"164","author":"Oliveira","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Yang, F., and Luo, J. (2024). The Association between Hepatitis C Virus Infection Status and Blood Pressure in Adults in the United States: NHANES 1999-2012. Front. Cell. Infect. Microbiol., 14.","DOI":"10.3389\/fcimb.2024.1401323"},{"key":"ref_16","first-page":"201","article-title":"The Impact of Infection with Hepatitis C Virus on Cardiovascular Risk","volume":"10","author":"Iorga","year":"2020","journal-title":"Am. J. Cardiovasc. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.18203\/2349-3933.ijam20203592","article-title":"Evolution of Arterial Hypertension in Patients with Hepatitis C Virus Cirrhosis after Antiviral Treatment","volume":"7","author":"Toma","year":"2020","journal-title":"Int. J. Adv. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41440-022-01117-6","article-title":"Mechanisms Underlying the Bidirectional Association between Nonalcoholic Fatty Liver Disease and Hypertension","volume":"46","author":"Nakagami","year":"2023","journal-title":"Hypertens. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3892\/ijmm.2013.1544","article-title":"Hypertension Exacerbates Liver Injury and Hepatic Fibrosis Induced by a Choline-Deficient L-Amino Acid-Defined Diet in Rats","volume":"33","author":"Arima","year":"2014","journal-title":"Int. J. Mol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/14656566.2024.2358139","article-title":"Revolutionizing Hepatitis C Treatment: Next-Gen Direct-Acting Antivirals","volume":"25","author":"Dobrowolska","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.3748\/wjg.v29.i25.4085","article-title":"Real-World Effectiveness and Safety of Direct-Acting Antivirals in Hepatitis C Virus Patients with Mental Disorders","volume":"29","author":"Dybowska","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e70007","DOI":"10.1002\/prp2.70007","article-title":"High Efficacy and Safety of Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: A Cohort Study Conducted in Vietnam","volume":"12","author":"Vo","year":"2024","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_23","first-page":"100658","article-title":"Treatment of HCV with Direct-Acting Antivirals on Reducing Mortality Related to Extrahepatic Manifestations: A Large Population-Based Study in British Columbia, Canada","volume":"29","author":"Jeong","year":"2024","journal-title":"Lancet Reg. Health Am."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Patel, S.V., Jayaweera, D.T., Althoff, K.N., Eron, J.J., Radtchenko, J., Mills, A., Moyle, G., Santiago, S., Sax, P.E., and Gillman, J. (2020). Real-World Efficacy of Direct Acting Antiviral Therapies in Patients with HIV\/HCV. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0228847"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Roguljic, H., Nincevic, V., Bojanic, K., Kuna, L., Smolic, R., Vcev, A., Primorac, D., Vceva, A., Wu, G.Y., and Smolic, M. (2021). Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.678546"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.jsps.2021.08.006","article-title":"The Effect of Direct Acting Antiviral Agents on Vascular Endothelial Function in Egyptian Patients with Chronic Hepatitis C Virus Infection","volume":"29","author":"Freekh","year":"2021","journal-title":"Saudi Pharm. J."},{"key":"ref_27","first-page":"16746","article-title":"Incidence and Prevalence of Registered Hypertension in Poland","volume":"134","author":"Prejbisz","year":"2024","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2020). EASL Recommendations on Treatment of Hepatitis C: Final Update of the Series\u2606. J. Hepatol., 73, 1170\u20131218.","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.5114\/jhi.2016.65356","article-title":"Prevalence of Hypertension in Polish Population of PURE Poland Study","volume":"2","author":"Szuba","year":"2016","journal-title":"J. Health Inequal."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Doyle, M.-A., Galanakis, C., Mulvihill, E., Crawley, A., and Cooper, C.L. (2019). Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but Not Glucose Parameters. Cells, 8.","DOI":"10.3390\/cells8030252"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Vranjkovic, A., Deonarine, F., Kaka, S., Angel, J.B., Cooper, C.L., and Crawley, A.M. (2019). Direct-Acting Antiviral Treatment of HCV Infection Does Not Resolve the Dysfunction of Circulating CD8+ T-Cells in Advanced Liver Disease. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01926"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3390\/v2081589","article-title":"Interferon-\u03bb in HCV Infection and Therapy","volume":"2","author":"Pagliaccetti","year":"2010","journal-title":"Viruses"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5114\/ceh.2016.63870","article-title":"Efficacy of HCV Treatment in Poland at the Turn of the Interferon Era\u2014The EpiTer Study","volume":"2","author":"Flisiak","year":"2016","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"7034","DOI":"10.1073\/pnas.0707882105","article-title":"Interferon Signaling and Treatment Outcome in Chronic Hepatitis C","volume":"105","author":"Oakeley","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1086\/630205","article-title":"Rate and Timing of Hepatitis C Virus Relapse after a Successful Course of Pegylated Interferon plus Ribavirin in HIV-Infected and HIV-Uninfected Patients","volume":"49","author":"Medrano","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/ceh.2023.125957","article-title":"Recommendations of the Polish Group of Experts for HCV for the Treatment of Hepatitis C in 2023","volume":"9","author":"Tomasiewicz","year":"2023","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/hep.29837","article-title":"Resistance Analysis of Genotype 3 Hepatitis C Virus Indicates Subtypes Inherently Resistant to Nonstructural Protein 5A Inhibitors","volume":"69","author":"Smith","year":"2019","journal-title":"Hepatology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.3748\/wjg.v27.i11.1006","article-title":"Genotype 3-Hepatitis C Virus\u2019 Last Line of Defense","volume":"27","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Zar\u0119bska-Michaluk, D., Jaroszewicz, J., Parfieniuk-Kowerda, A., Janczewska, E., Dybowska, D., Paw\u0142owska, M., Halota, W., Mazur, W., Lorenc, B., and Janocha-Litwin, J. (2021). Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics. J. Clin. Med., 10.","DOI":"10.3390\/jcm10153280"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1086\/423384","article-title":"Strong Association of Hepatitis C Virus (HCV) Infection and Thrombocytopenia: Implications from a Survey of a Community with Hyperendemic HCV Infection","volume":"39","author":"Wang","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0168-8278(02)00274-X","article-title":"Serum Thrombopoietin Levels Are Linked to Liver Function in Untreated Patients with Hepatitis C Virus-Related Chronic Hepatitis","volume":"37","author":"Giannini","year":"2002","journal-title":"J. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1046\/j.1365-2141.2001.02824.x","article-title":"Hepatic Fibrosis Plays a Central Role in the Pathogenesis of Thrombocytopenia in Patients with Chronic Viral Hepatitis","volume":"113","author":"Adinolfi","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1177\/106002809502900901","article-title":"Thrombocytopenia in Intensive Care Patients: A Comprehensive Analysis of Risk Factors in 314 Patients","volume":"29","author":"Bonfiglio","year":"1995","journal-title":"Ann. Pharmacother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.hoc.2007.06.005","article-title":"Drug-Induced Thrombocytopenia","volume":"21","author":"Visentin","year":"2007","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"ref_45","first-page":"e42918","article-title":"Calcium Channel Blocker-Induced Thrombocytopenia in the Intensive Care Unit: A Rare Presentation and Review of the Literature","volume":"15","author":"Zhou","year":"2023","journal-title":"Cureus"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/jgh.13587","article-title":"Effectiveness and Safety of Daclatasvir plus Asunaprevir for Hepatitis C Virus Genotype 1b: Systematic Review and Meta-Analysis","volume":"32","author":"Wang","year":"2017","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40261-022-01150-w","article-title":"Management of Pharmacologic Adverse Effects in Advanced Liver Disease","volume":"42","year":"2022","journal-title":"Clin. Drug Investig."},{"key":"ref_48","first-page":"465","article-title":"Prevalence of the Potential Drug\u2013Drug Interactions between Pangenotypic Direct-Acting Antivirals and the Concomitant Medications Associated with Patients with Chronic Hepatitis C Virus Infection in Spain","volume":"42","author":"Morillo","year":"2019","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40262-018-0710-1","article-title":"Cardiovascular Risk Management and Hepatitis C: Combining Drugs","volume":"58","author":"Smolders","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_50","first-page":"331","article-title":"Drug-Drug Interactions between Direct-Acting Antivirals and Statins in the Treatment of Chronic Hepatitis C","volume":"32","author":"Kuo","year":"2020","journal-title":"Ci Ji Yi Xue Za Zhi"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1007\/s12072-022-10402-y","article-title":"Drug-Drug Interactions between Direct-Acting Antivirals and Co-Medications: A Territory-Wide Cohort Study","volume":"16","author":"Hui","year":"2022","journal-title":"Hepatol. Int."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3748\/wjg.v23.i9.1618","article-title":"Optimizing Hepatitis C Virus Treatment through Pharmacist Interventions: Identification and Management of Drug-Drug Interactions","volume":"23","author":"Langness","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Borghi, C., Ciancio, A., Gentile, I., Perrone Filardi, P., Pasqualetti, P., and Brillanti, S. (2022). Evaluation of Drug Interactions in Patients Treated with DAAs for Hepatitis C Therapy with Comorbidities and Cardiovascular Issues-A Delphi Consensus Project. J. Clin. Med., 11.","DOI":"10.3390\/jcm11236946"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"322","DOI":"10.14218\/JCTH.2020.00034","article-title":"Review of Clinically Relevant Drug Interactions with next Generation Hepatitis C Direct-Acting Antiviral Agents","volume":"8","author":"Hong","year":"2020","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jval.2022.09.238","article-title":"CO162 Association between Hypotension and Drug Interaction of Direct-Acting Antiviral Agents in Hepatitis C Virus-Infected Patients: A Multicenter Study in Taiwan","volume":"25","author":"Hsu","year":"2022","journal-title":"Value Health"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1177\/1060028015576180","article-title":"Drug Interactions with Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients","volume":"49","author":"Burgess","year":"2015","journal-title":"Ann. Pharmacother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.yclnex.2018.04.001","article-title":"Body Weight Control and Energy Expenditure","volume":"20","author":"Fonseca","year":"2018","journal-title":"Clin. Nutr. Exp."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/sms.13955","article-title":"Resting Metabolic Rate Is Increased in Hypertensive Patients with Overweight or Obesity: Potential Mechanisms","volume":"31","author":"Acosta","year":"2021","journal-title":"Scand. J. Med. Sci. Sports"},{"key":"ref_59","first-page":"e57825","article-title":"Statins as Anti-Hypertensive Therapy: A Systematic Review and Meta-Analysis","volume":"16","author":"Khan","year":"2024","journal-title":"Cureus"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/7\/763\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T09:52:59Z","timestamp":1783936379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/7\/763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,12]]},"references-count":59,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["v18070763"],"URL":"https:\/\/doi.org\/10.3390\/v18070763","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,12]]}}}